A Phase 2B Multicenter, Randomized, Double-Blind, Comparative Trial Of UK-453,061, In Combination With Tenofovir Df And Emtricitabine Versus Efavirenz In Combination With Tenofovir Df And Emtricitabine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects

Trial Profile

A Phase 2B Multicenter, Randomized, Double-Blind, Comparative Trial Of UK-453,061, In Combination With Tenofovir Df And Emtricitabine Versus Efavirenz In Combination With Tenofovir Df And Emtricitabine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2016

At a glance

  • Drugs Lersivirine (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Mar 2012 This trial is recruiting in United Kingdom.
    • 04 Aug 2011 Status changed from active, no longer recruiting to completed.
    • 04 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top